References
Original article
Wang, K. et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat. Med. https://doi.org/10.1038/s41591-023-02786-7 (2024)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. Adjuvant sintilimab effective in high-risk HCC. Nat Rev Clin Oncol 21, 168 (2024). https://doi.org/10.1038/s41571-024-00865-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-024-00865-3
- Springer Nature Limited